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Dilated cardiomyopathy (DCM) is characterized by a metabolic shift from fat to carbohydrates and failure to increase myocardial
glucose uptake in response toworkload increments.We verifiedwhether this pattern is influenced by an abnormal glucose tolerance
(AGT). In 10 patients with DCM, 5 with normal glucose tolerance (DCM-NGT) and 5 with AGT (DCM-AGT), and 5 non-DCM
subjects with AGT (N-AGT), we measured coronary blood flow and arteriovenous differences of oxygen and metabolites during
Rest, Pacing (at 130 b/min), and Recovery. Myocardial lactate exchange and oleate oxidation were also measured. At Rest, DCM
patients showed a reduced nonesterified fatty acids (NEFA) myocardial uptake, while glucose utilization increased only in DCM-
AGT. In response to Pacing, glucose uptake promptly rose in N-AGT (from 72 ± 21 to 234 ± 73 nmol/min/g, 𝑝 < 0.05), did not
change in DCM-AGT, and slowly increased in DCM-NGT. DCM-AGT sustained the extra workload by increasing NEFA oxidation
(from 1.3 ± 0.2 to 2.9 ± 0.1 𝜇mol/min/gO
2
equivalents, 𝑝 < 0.05), while DCM-NGT showed a delayed increase in glucose uptake.
Substrate oxidation rates paralleled the metabolites data. The presence of AGT in patients with DCM exacerbates both the shift
from fat to carbohydrates in resting myocardial metabolism and the reduced myocardial metabolic flexibility in response to an
increased workload. This trial is registered with ClinicalTrial.gov NCT02440217.
1. Introduction
The relationships between diabetes and impaired glucose
tolerance (defined together as conditions of abnormal glucose
tolerance, AGT) and dilated cardiomyopathy (DCM) are
complex both at the clinical and the biochemical levels.
Patients with AGT are more prone to develop both ischemic
and nonischemic DCM [1–3] and derangements in glucose
homeostasis are more prevalent among patients with DCM
than in the general population [4]. The changes in whole-
body metabolism, which are mainly secondary to insulin
resistance and present in either AGT or DCM patients
[5, 6], are expected to profoundly and similarly affect the
heart, given the large reliance of myocardial metabolism
on circulating substrates [7]. Despite this, the derangements
in myocardial metabolism that have been described in the
two conditions are opposite: while nonesterified fatty acids
(NEFA) uptake and oxidation are reduced in primary DCM
[8, 9], both are enhanced in diabetes [10], whereas glucose
uptake and oxidation are depressed in diabetes and enhanced
in DCM [9]. Therefore, particularly in DCM patients, the
glucose tolerance status is expected to exert a relevant
influence on myocardial metabolism and could justify the
discrepancies of the data on myocardial metabolism in DCM
[11].Whether the above-mentioned changes contribute to the
disease progression or are compensatory is unclear; while an
excess uptake of NEFA would contribute to myocardial dam-
age [12], a shift from lipids to carbohydrate would support
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myocardial energetics [13]. In addition to an abnormal
metabolism in resting/fasting conditions, animal and human
studies have demonstrated that both the failing myocardium
and the diabetic myocardium display a reduced metabolic
flexibility in response to substrate manipulations and to
an increase in workload [12]. Therefore, chronic metabolic
changes, which in certain conditions are adaptive, might ren-
der the myocardium unable to cope with stress. The changes
in myocardial metabolism at baseline and in response to
stress when impaired glucose metabolism and DCM are
simultaneously present are unknown and might influence
the process of (mal) adaptation. Interestingly, epidemiologic
studies have suggested that diabetes does not worsen the
prognosis of nonischemic DCM [14] and indeed in patients
with DCM [15] higher fasting glucose levels are associated
with a better prognosis; it is therefore possible that the
opposing metabolic changes are somehow compensatory.
Our hypothesis is that the diabetic milieu attenuates the
myocardial metabolic abnormalities of DCM, but it further
reduces the already poormetabolic flexibility of the organ. To
reduce the confounding effects of the systemic hormonal and
substrate changes induced by either diseases and/or by their
treatments, and also the variability induced by the different
aetiology of DCM, we accurately selected only patients with
NYHA class II/III idiopathic DCM and impaired glucose
tolerance (IGT) or diet-controlled type 2 diabetes, with
normal or impaired fasting glucose (<7.0mmol/L).
2. Methods
The study was approved by the Ethics Committee of Institute
of Clinical Physiology which is an autonomous institution
of the National Research Council, and a written informed
consent was obtained from each candidate on the day before
cardiac catheterization after an exhaustive explanation of the
protocol and its potential risks.
2.1. Study Population. We enrolled 5 patients with DCM and
normal glucose tolerance (DCM-NGT) at the standard 75 g
oral glucose tolerance test (OGTT), 5 patients with DCM
and with either IGT or diabetes at the OGTT (DCM-AGT),
and 5 patients with normal left ventricular function but
with either IGT or diabetes at the OGTT (N-AGT). The
subjects were preselected on the bases of clinical history,
OGTT results, and left ventricular function, and they were
admitted to the Cardiology Department of the NRC Institute
of Clinical Physiology to undergo a diagnostic coronary
angiography. If the subject had angiographically normal
coronary arteries, then he/she was enrolled in the study.
DCMwas defined as left ventricular ejection fraction (LVEF)
<40% and left ventricular end diastolic diameter (LVEDD)
>56mm. Exclusion criteria were NYHA class IV, atrial fib-
rillation, age ≥70 or ≤20 yrs, previous myocardial infarction,
valvular heart disease, myocarditis or pericarditis, severe
to moderate systemic arterial hypertension, fasting hyper-
glycaemia (>7.0mmol/L) or treated diabetes, autoimmune
diseases, neoplasia, and kidney, liver, or respiratory failure.
N-AGT patients underwent coronary angiography because
of either history of angina-like chest pain and/or previous
stress tests suspicious for myocardial ischemia. Normal left
ventricular function was defined as LVEF >50% and LVEDD
<56mm. All coronary-active drugs, including nitrates, Ca++-
antagonists,𝛽-blockers, andACE-inhibitors, were suspended
at least 24 hours before catheterization.
2.2. Cardiac Catheterization. A 6F guide catheter was placed
in the left main coronary ostium through a 7F femoral artery
introducer. An intracoronary heparin bolus (100U/Kg) was
given and a 0.014Doppler flowwire (FloWire, VolcanoCorp.)
was advanced into the LAD. A 2.9 F, 10MHz intravascular
ultrasound (IVUS) catheter (Eagle Eye Gold, Volcano Corp.)
was passed over the flow wire and positioned in the LAD
immediately distal to the first septal perforating branch. The
position of the IVUS catheter and flow wire was documented
by angiography and was verified throughout the study by
fluoroscopic control. After calibration, phasic and mean
coronary perfusion pressure (from the guiding catheter) and
coronary flow velocity signals were continuously recorded
together with ECG (leads DI-DII-DIII). IVUS images were
obtained for ≥30 seconds at each step of the protocol,
with temporal synchronization with flow velocity signal, and
recorded for offline analysis. After LAD instrumentation, a
5F catheter was advanced into the coronary sinus, up to the
great cardiac vein, to withdraw venous blood from the LAD
territory.Then, a unipolar pacing catheterwas positioned into
the right atrium. Arterial sampling was done from the 7F
femoral artery introducer catheter.
2.3. Study Protocol. The study protocol consisted of three
steps: Rest, Pacing, and Recovery. After the instrumentation
was completed (about 30min), Rest arteriovenous sampling
was performed at times−15min and 0min.After 0min, heart
rate was increased by atrial pacing to 110 bpm for 3 minutes
and to 130 bpm for 3 additional minutes and arteriovenous
sampling was repeated at the end of each step (at times 3
and 6min). Pacing was then stopped and at times 1, 5, 15,
and 30min into the Recovery period other pairs of arterial
and venous samples were withdrawn. The first 5mL of blood
from each line was discarded to avoid contamination and
then blood samples were transferred in ad hoc prepared
tubes and kept in ice. In 4 N-AGT and in 5 DCM-AGT
subjects, paired A-V blood samples were also collected in
heparinised syringes and gas analysis immediately executed
(Instrumentation Laboratory, Blood Gas Analyser IL 1620,
Bedford, MA). In 5 N-AGT, in 4 DCM-AGT, and in 4 DCM-
NGT, after the completion of diagnostic angiography, a bolus
of 110mg of [3-13C]-L-lactate and 50 𝜇Ci of [9,103H]-oleate
was followed by i.v. continuous infusion of [9,103H]-oleate
(84 𝜇Ci/h) and [3-13C]-L-lactate (130mg/h) allowing a 30-
minute equilibration period. The lactate stable isotope was
used to measure net lactate uptake and net lactate release
from the myocardium by the difference with the unlabelled
lactate exchange. Labelled oleate was used to measure frac-
tional oleate extraction and the fraction of oleate undergoing
oxidation from the measurement of the myocardial 3H
2
O
production [16].
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2.4. Assays and Calculations
2.4.1. Hemodynamics. Mean flow velocity was derived from
the Doppler wire signal as the average time of spectral peak
velocity. LAD lumen area (IVUS) was computed in systole
and diastole for different cardiac cycles and then averaged.
The absolute coronary blood flow (CBF) in the LAD was
obtained by the formula
CBF (mL/min) = mean flow velocity (cm/sec)
∗ LAD lumen area (cm2) ∗ 60.
(1)
Since DCM and N-AGT patients had very different LV
masses, CBF values were corrected for the estimated LAD-
dependent myocardial mass using the following formula:
CBF (m/min/g) = CBF (mL/min)
(0.54 ∗ LVmass (g))
. (2)
The fraction of LV mass putatively supplied by the LAD
(0.54) was chosen based on the following considerations.
First, in noninvasive wall motion or perfusion studies, 8–12
out of 17 LV segments (43–65%, average 54%) are attributed
to LAD [17, 18]. Second, in 6DCMpatients of our population,
absolute blood flow in the LAD territory (mL/min/g) was
independently measured by PET and 13N-ammonia, and the
agreement between the directly measured and the calculated
values was good (0.61 ± 0.18 versus 0.56 ± 0.13mL/min/g,
𝑝 = ns).
2.4.2. Metabolites. Whole blood glucose, lactate and 𝛽-
OH-butyrate, pyruvate, glycerol and alanine, and serum
triglycerides were determined spectrophotometrically on a
Beckman Synchron CX7 analyser (Global Medical Instru-
mentation, Ramsey, MN, USA). Whole blood samples were
collected into iced tubes containing 1M perchloric acid and
the supernatant was stored at –20∘C and assayed within 30
days. NEFA concentration was determined in plasma after
centrifugation of EDTA-treated blood samples using a colori-
metric assay (Wako Chemicals Gmbh, Neuss, Germany).
2.4.3. Isotopes. The isotopic enrichment of lactate with [13C]-
L-lactate was measured by gas chromatography-mass spec-
trometry in plasma samples deproteinized with perchloric
acid and derivatized using N-methyl-N-(t-butyldimethylsil-
yl)-trifluoroacetamide (Sigma, St. Louis, MO, USA). Plasma
[9,103H]-oleate concentration was measured by extracting
fatty acids from 0.5mL of plasma in 3mL of HCl-heptane-
isopropanol (1 : 10 : 40) and counting the radioactivity of the
organic phase with a liquid scintillation counter (model LS
6500; Beckman) while 3H
2
O concentration, derived from
[9,10-3H] oleate oxidation, was measured by counting the
water phase. Myocardial substrate uptake, release, and oxi-
dation were calculated as the arteriovenous concentration
difference times CBF as previously described [19].
2.4.4. Gas Analysis and Oxygen Equivalent Calculations.
TotalO
2
andCO
2
blood content were calculated as previously
described [20]. Carbohydrate and lipid oxidation rates and
energy expenditure were calculated using standard equation
for indirect calorimetry as explained in detail in [21]. Sub-
strates oxygen equivalents were calculated on the bases of
the predictedATP yields generated by the complete oxidation
of each glucose, lactate, 𝛽-OH-butyrate, and oleate molecule
taken up by themyocardial tissue (36, 12, 24, and 131 permole,
resp.) that was converted in oxygen according to the substrate
specific ATP/O
2
ratio (oleate: 5.6mol/mol; glucose, lactate,
and 𝛽-OH-butyrate: 6mol/mol) [21]. Values were averaged
over the 3 study periods using the following samples: Rest
(−10 and 0min), Pacing (3 and 6min), and Recovery (11, 16,
and 31min).
2.4.5. Statistics. Data are presented as mean ± SEM. Dif-
ferences in mean and prevalence were tested with the
Wilcoxon/Kruskal-Wallis and 𝐶ℎ𝑖2 tests, respectively. Differ-
ences in coronary hemodynamic and metabolic data were
compared between study conditions (Rest, Pacing, and Recov-
ery) by one-way ANOVA for repeated measure and within
each study condition between groups by two-way ANOVA
for single repeated measure over time and the least square
mean estimates ± SEM are given. 𝑝 value less than 0.05 was
considered significant.
3. Results
3.1. Clinical Characteristics of the Study Populations. The
clinical characteristics of the 3 study groups are shown in
Table 1.The groups did not significantly differ in terms of age,
gender distribution, BMI, fasting glucose, and fasting insulin.
History of angina-like chest pain was more frequent in N-
AGT groups. DCM patients showed symptoms and echocar-
diographic and serum indices (NT-proBNP and BNP) and
drug treatments, suggesting a non-severely compromised LV
systolic function which was of similar degree in AGT and
NGT.The 2 groups of AGT subjects, N andDCM, had similar
fasting and 2 h OGTT glucose values, while DCM subjects
showed higher fasting serum triglycerides.
3.2. Coronary Haemodynamic. Data on coronary hemody-
namic during and after pacing stress are summarized in
Figure 1.While heart rateswere superimposable in the 3 study
groups, rate pressure product tended to be higher in N-AGT
(𝑝 = 0.11), with mean blood pressure being significantly
higher in this study group, with respect to DCM-AGT and
NGT patients (107 ± 4 versus 87 ± 5 and 90 ± 4mmHg,
𝑝 < 0.01), throughout the study. Coronary specific blood flow
in the LAD territory, during both Rest and Pacing, was lower
in DCM-NGT than in N-AGT (𝑝 < 0.05) with the values
in DCM-AGT being intermediate, though not statistically
different from the other groups. In the Recovery, coronary
blood flow was similar in the 3 study groups; however, with
respect to Rest, N-AGT reached blood flow values that were
significantly lower (𝑝 < 0.05), while the other 2 study groups
returned to baseline.
3.3. Myocardial Metabolism and Energetics. Arterial whole
blood concentrations of lactate (0.565 ± 0.074 versus 0.515 ±
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Table 1: Clinical characteristics of the study populations.
N-AGT DCM-NGT DCM-AGT
𝑁 5 5 5
Age (year) 62 ± 6 55 ± 3 60 ± 6
Males/females (𝑛) 3/2 4/1 3/2
Angina (𝑛) 5 2 1
NYHA class II/III (𝑛) 1/0 3/2∗ 3/2∗
LV mass (g) 175 ± 16 288 ± 27∗ 292 ± 43∗
LVEF (%) 56 ± 2 34 ± 2∗ 31 ± 1∗
LVEDD (mm) 51 ± 2 64 ± 2∗ 66 ± 2∗
BNP (pg/mL) 20 ± 7 98 ± 22∗ 104 ± 30∗
NT-proBNP (pg/mL) 128 ± 37 598 ± 130∗ 604 ± 127∗
Body mass index (kg/m2) 28 ± 2 29 ± 2 30 ± 2
Fasting insulin (pmol/L) 77 ± 8 69 ± 9 84 ± 10
Fasting glucose (mmol/L) 5.6 ± 0.2 5.4 ± 0.2 5.8 ± 0.2
OGTT 2 h glucose (mmol/L) 10.8 ± 1.1 6.0 ± 0.6∗ 10.9 ± 0.7§
Triglycerides (mmol/L) 0.66 ± 0.10 0.65 ± 0.19 1.14 ± 0.20§
𝛽-blockers (𝑛) 3 5 5
ACE-inhibitors/AT-1 antagonists (𝑛) 4 5 5
Antialdosteronic agents (𝑛) 0 3∗ 4∗
Furosemide ≥25mg/die (𝑛) 1 5∗ 5∗
LV mass: left ventricular mass; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter.
∗
𝑝 < 0.05 for the comparison with N-AGT.
§
𝑝 < 0.05 for the comparison between DCM-NGT and AGT.
0.073 versus 0.697 ± 0.070mmol/L) and glucose (4.6 ± 0.2
versus 4.9±0.2 versus 4.9±0.2mmol/L)were similar inN-AGT
versus DCM-NGT versus DCM-AGT, whereas whole blood
𝛽-OH-butyrate was higher in DCM-NGT (0.272 ± 0.078
versus 0.704±0.202 versus 0.139±0.043mmol/L) and plasma
NEFAwas higher inN-AGT (1.758±0.105 versus 1.178±0.158
versus 1.412 ± 0.149mmol/L) (𝑝 < 0.02 for both). None of
these arterial concentrations changed during the study.
With respect to N-AGT, the patients with DCM (NGT
and AGT altogether) in Rest showed a 60% reduction
in myocardial NEFA uptake 60% (59 ± 10 versus 186 ±
18 nmol/min/g, 𝑝 = 0.001) and a doubling of myocar-
dial glucose uptake (135 ± 15 versus 73 ± 8 nmol/min/g,
𝑝 = 0.013) (Figure 2). Although glucose uptake was not
statistically different between DCM-NGT and DCM-AGT,
the increase with respect to N-AGT was more pronounced
(+120%) in the latter than in the former (+48%).The reduced
NEFA uptake was not determined by a lower extraction rate
(14±2 versus 16±2%,𝑝 = ns) but by the combination of lower
arterial NEFA (1.944±0.155 versus 1.251±0.129mmol/L,𝑝 <
0.0001) and lower myocardial blood flow (0.89 ± 0.08 versus
0.71 ± 0.07mL/min/g, 𝑝 = 0.03). Similar NEFA extraction
was confirmed by labelled oleate data (31 ± 3 versus 35 ± 3%)
that, in absolute values, were also higher than the estimates
obtained with natural substrates as previously reported [22].
Oleate and 3H
2
O data also indicated a similar fractional
oxidation rate in normal and DCM patients (66 ± 7 versus
64 ± 6%).
In Rest, lactate uptake was particularly low in DCM-
NGT and 𝛽-OH-butyrate uptake was particularly low in
DCM-AGTwith respect to the other study groups (Figure 2).
Neither glycerol nor alanine nor triglycerides net balances
were significantly different from zero (Table 2). Pyruvate
uptake, although still quantitatively minute (10% of lactate
uptake), was not different from zero in DCM-AGT, while it
was null in DCM-NGT.
In response to pacing, DCM-NGT showed a delayed and
persistent increase in glucose, NEFA, and 𝛽-OH-butyrate
uptake, while DCM-AGT showed a short lasting increment
only in NEFA and lactate coupled with a reduction in
glucose and no change in 𝛽-OH-butyrate uptake (Figure 2).
Once we compared the contribution of the readily oxidised,
small size, high respiratory quotient substrates (glucose,
lactate, and 𝛽-OH-butyrate) with the NEFA oxidation rates
measured by tracer, we observed that DCM-NGT paid the
extra work induced by pacing increasing the utilization of
small molecules, mostly in the Recovery period, while DCM-
AGT sustained the myocardial work by a short lasting rise
in NEFA oxidation being unable to modify the utilization of
the other substrates (Figure 3). The N-AGT subjects fuelled
the pacing with a prompt increase in glucose and small
molecules uptake that persisted 15min into the Recovery
period. Interestingly, the rise in NEFA oxidation in DCM-
AGT patients was determined by a rise in both NEFA net
balance (from 54 ± 32 to 75 ± 29 nmol/min/g, 𝑝 < 0.05)
and fractional oxidation (from 72 ± 8 to 93 ± 9, 𝑝 < 0.05) as
estimated from oleate conversion into 3H
2
O. Neither glycerol
nor alanine nor pyruvate nor triglycerides net balances were
significantly different from Rest during Pacing or Recovery
(Table 2).
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Figure 1: Heart rate, rate pressure product (RPP), and myocardial blood flow (MBF) in 5 N-AGT (gray line), 5 DCM-NGT (dotted black
line), and 5 DCM-AGT (continuous black line) in the 3 phases of the study protocol: Rest, Pacing, and Recovery. The plotted values are mean
± SEM.The thin gray lines represent the SEM of the N-AGT group.
The metabolic inflexibility of DCM-AGT patients is con-
firmed also by myocardial gas exchange data that shows that
the extra cardiac work is almost entirely supported by lipid,
whilst in N-AGT it is supported by carbohydrates oxidation
(Table 3).
The myocardial release of lactate estimated by tracer was
only minimally stimulated by pacing but promptly returned
to baseline values, suggesting no evidence of metabolic
ischemia in either study group (Figure 4).
4. Discussion
We confirm that patients with DCM have a reduced myocar-
dial NEFA uptake and oxidation, a tendency to an enhanced
myocardial glucose utilization, and a reduced metabolic
flexibility to face an extra energy demand [8]. The novel
aspect is that abnormal glucose tolerance does not modify
resting heart metabolism but is associated with a more severe
metabolic inflexibility that involves other metabolites: while
6 Journal of Diabetes Research
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Figure 2: Cardiac glucose (a), lactate (b), NEFA (c), and 𝛽-OH-butyrate (d) uptake in 5 N-AGT (gray line), 5 DCM-NGT (dotted black line),
and 5 DCM-AGT (continuous black line) in the 3 phases of the study protocol: Rest, Pacing, and Recovery. The plotted values are mean ±
SEM.The thin gray lines represent the SEM of the N-AGT group.
Table 2: Cardiac net balances of other metabolites.
N-AGT DCM-NGT DCM-AGT 𝑝
Alanine
(nmol/min/g)
𝑅𝑒𝑠𝑡 −17.4 ± 6.3 −7.9 ± 3.4 −7.5 ± 7.6
ns𝑃𝑎𝑐𝑖𝑛𝑔 −16.8 ± 6.8 −14.1 ± 4.2 −8.8 ± 5.2
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 −18.2 ± 8.1 −5.1 ± 6.7 −8.0 ± 3.1
Pyruvate
(nmol/min/g)
𝑅𝑒𝑠𝑡 12.9 ± 5.8 3.9 ± 2.4 24.8 ± 6.1
<0.05𝑃𝑎𝑐𝑖𝑛𝑔 14.1 ± 5.0 3.8 ± 1.9 32.4 ± 8.1
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 14.6 ± 4.7 −1.9 ± 2.8 22.6 ± 3.8
Glycerol
(nmol/min/g)
𝑅𝑒𝑠𝑡 −0.3 ± 3.4 2.8 ± 2.5 1.6 ± 2.9
ns𝑃𝑎𝑐𝑖𝑛𝑔 −0.1 ± 3.9 −4.6 ± 5.1 −5.5 ± 8.9
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 −2.1 ± 2.6 −1.6 ± 3.9 −2.0 ± 1.9
Triglycerides
(nmol/min/g)
𝑅𝑒𝑠𝑡 1.7 ± 5.4 6.0 ± 2.8 3.7 ± 7.1
ns𝑃𝑎𝑐𝑖𝑛𝑔 7.6 ± 4.1 3.5 ± 5.6 −4.6 ± 5.1
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 7.1 ± 7.4 7.0 ± 4.3 4.2 ± 3.2
Metabolite concentrations were available for all patients: 5 N-AGT, 5 DCM-NGT, and 5 DCM-AGT.
𝑝 values refer to the comparison between N-AGT and DCM-AGT as estimated by 2-way ANOVA for one repeated measure over time.
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Figure 3: Cardiac energy generation expressed on oxygen equivalents from (a) small molecules, blood born, readily oxidizable substrates
(calculated summing up glucose, lactate, and 𝛽-OH-butyrate net balances and assuming their full oxidation) as compared to energy generated
by NEFA oxidation as measured from [9,103H]-oleate conversion to 3H
2
O in 5 N-AGT (gray line), 4 DCM-NGT (dotted black line), and 4
DCM-AGT (continuous black line) in the 3 phases of the study protocol: Rest, Pacing, and Recovery. The plotted values are mean ± SEM.The
thin gray lines represent the SEM of the N-AGT group. ∗ indicates a 𝑝 < 0.05 for the comparison between DCM-AGT and DCM-NGT over
the study phase by 2-way ANOVA for repeated measures.
in NGT we observed a delay in the shift to glucose and other
small molecules (lactate and 𝛽-OH-butyrate) utilization, in
AGT patients the use of small molecules resulted to be fixed
and the extra work was done entirely relying upon NEFA.
We also found that the reduction in NEFA uptake is
essentially caused by a reduced substrate supply (i.e., blood
flow and arterial concentration) and not by an impaired
substrate extraction. This finding was confirmed by the
tracer exchange data that revealed similar extraction rates
in N and DCM despite the different net balances. The
discrepancy between the tracer and the natural substrate
estimated tissue extraction, which has already been observed
and extensively discussed [22], was similar in N-AGT, DCM-
NGT, and DCM-AGT as can be appreciated comparing the
slope values yielded by regression analysis (forced to a 0
intercept) on the two independent estimates within each
study group (1.55 ± 0.12, 1.46 ± 0.17, and 1.46 ± 0.16,
resp.). Similar NEFA and [2H
2
]-palmitate extraction rates
have also recently been reported in DCM patients and type
2 diabetic patients with normal left ventricular function [23];
however, having not measured blood flow but only oxygen
uptake, the authors could not detect the presence of absolute
reduction in metabolic fluxes in DCM patients. The overall
similarity between DCM-NGT and DCM-AGT in resting
conditions is against our hypothesis that abnormal glucose
metabolism would oppose the chronic metabolic shift of
DCM patients. The presence of DCM imposes a change to
myocardial metabolism that prevails on the consequences
of a systemic derangement in glucose metabolism. The less
severe alteration in glucose and lactate uptake in DCM-NGT
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Table 3: Gas analysis data.
Phase N-AGT DCM-AGT 𝑝
MVO
2
(𝜇mol/min/g)
𝑅𝑒𝑠𝑡 5.7 ± 0.6 4.1 ± 0.6
ns𝑃𝑎𝑐𝑖𝑛𝑔 6.5 ± 0.6∗ 5.1 ± 0.4∗
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 5.1 ± 0.4 3.4 ± 0.2
RQ
𝑅𝑒𝑠𝑡 0.80 ± 0.05 0.80 ± 0.10
<0.05𝑃𝑎𝑐𝑖𝑛𝑔 0.82 ± 0.03 0.77 ± 0.05
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 0.85 ± 0.04 0.88 ± 0.10
Carbohydrates oxidation
(nmol/min/g)
𝑅𝑒𝑠𝑡 402 ± 83 230 ± 145
<0.02𝑃𝑎𝑐𝑖𝑛𝑔 767 ± 58∗ 208 ± 67
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 450 ± 102 362 ± 103
Lipids oxidation
(nmol/min/g)
𝑅𝑒𝑠𝑡 160 ± 73 83 ± 32
<0.02𝑃𝑎𝑐𝑖𝑛𝑔 179 ± 44 159 ± 35∗
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 101 ± 20 62 ± 33
EE from carbohydrates
(cal/min/g)
𝑅𝑒𝑠𝑡 0.26 ± 0.13 0.15 ± 0.08
<0.02𝑃𝑎𝑐𝑖𝑛𝑔 0.51 ± 0.04∗ 0.14 ± 0.06
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 0.30 ± 0.09 0.24 ± 0.09∗
EE from lipids
(cal/min/g)
𝑅𝑒𝑠𝑡 0.38 ± 0.09 0.20 ± 0.10
<0.02𝑃𝑎𝑐𝑖𝑛𝑔 0.43 ± 0.11 0.38 ± 0.08∗
𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 0.33 ± 0.09 0.21 ± 0.08
Gas analysis data were available for a subset of patients: 4 DCM-NGT and 4 DCM-AGT.
𝑝 values refer to the comparison between N-AGT and DCM-AGT as estimated by 2-way ANOVA for one repeated measure over time.
∗
𝑝 < 0.05 for the comparison with the preceding study protocol step (𝑃𝑎𝑐𝑖𝑛𝑔 versus 𝑅𝑒𝑠𝑡 and 𝑅𝑒𝑐𝑜V𝑒𝑟𝑦 versus 𝑃𝑎𝑐𝑖𝑛𝑔).
MVO2: myocardial oxygen uptake; RQ: respiratory quotient; EE: energy expenditure.
Rest
Pacing
Recovery
Time (min) 
−20 −10 0 10 20 30 40
0
50
100
150
200
250
300
La
ct
at
e r
ele
as
e (
nm
ol
/m
in
/g
)
Figure 4: Cardiac lactate release as estimated subtracting [3-13C]-
L-lactate cardiac uptake to the natural substrate net balance in 5 N-
AGT (gray line), 4 DCM-NGT (dotted black line), and 4DCM-AGT
(continuous black line) in the 3 phases of the study protocol: Rest,
Pacing, and Recovery. The plotted values are mean ± SEM. The thin
gray lines represent the SEM of the N-AGT group.
suggest that the enhanced carbohydrate utilization is peculiar
of patients with DCM and AGT and this might explain why
these findings are not consistent in the literature. The resting
lower rates of 𝛽-OH-uptake in DCM-AGT are probably only
the consequence of the lower arterial levels of the substrate.
Myocardial metabolic response to stress in DCMpatients
with and without AGT had not previously been investigated.
In normal hearts, high rate pacing induces a rapid increase
in glucose and lactate uptake coupled with a relative decline
in NEFA uptake [24, 25]. Clinical and experimental studies
suggest that this response is advantageous and increases
myocardial mechanical efficiency as carbohydrates are more
efficient substrates than lipids since they providemore energy
for any given amount of oxygen consumed [26–28]. The
metabolic response to pacing in DCM patients was different
according to glucose tolerance status: DCM-AGT showed a
complete inability to shift to glucose and/or small molecules
utilization, and in DCM-NGT the shift was delayed. The
inflexibility of DCM-AGTwas also confirmed by gas analysis
data that yielded estimates that were very close to natural sub-
strate and tracer-derived data. Interestingly, these data also
indicate that bothRest and Pacing oxygen uptake (and energy
expenditure) per g of tissue are approximately 40–50% lower
in DCM patients suggesting a reduced myocardial energetics
density (per g of tissue); however, the small sample size and
the lack of accurate measurements of cardiac work prevent
from quantitatively comparing the energetic efficiency in the
two groups. The normal aerobic metabolism (i.e., lack of
the metabolic fingerprints of ischemia) is also independently
and directly confirmed by lactate tracer-derived release data
during either Pacing or Recovery in each and all study
groups (Figure 4). The presence of AGT therefore worsens
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the already impaired metabolic flexibility observed in DCM
patients.The inability to use high respiratory quotient, readily
oxidizable, blood born small molecules to sustain a rapid
increase in energy demand is rather surprising particularly in
a tissue where the oxidation of themajor alternative substrate
(NEFA) is depressed and is also more demanding in terms
of oxygen. One possible explanation is that in DCM-AGT
NEFA oxidation can increase because there is an increase
in myocardial blood flow that is less evident in DCM-NGT
patients who, therefore, must rely upon alternative blood
born substrates. Clearly, there must be other explanations
since we also observed a more efficient oleate fractional
oxidation in DCM-AGT during pacing. One of the possible
mechanisms explaining the metabolic inflexibility of the fail-
ing heart is the paradoxical downregulation of key enzymes
of the carbohydrate oxidative pathway, in spite of a higher
glucose oxidation rate, as it has previously been described in
dogs [29].
Given the pathophysiologic nature of the question
addressed and of the methods employed, the clinical conse-
quences of our findings remain entirely speculative. The lack
of flexibility, if confirmed, would expose the myocardium to
a lesser energetic efficiency (higher oxygen cost for NEFA
oxidation rather than small molecules) and potentially to
a dangerous reliance on plasma NEFA availability, whose
plasma concentration, for example, is dramatically reduced
in the postabsorptive state. In the long term, it would be
important to understand whether the different responses
to pacing observed in AGT and NGT are adaptative or
maladaptative and/orwhether theymodify the natural course
of the myocardial disease. This might influence the clinical
response to drugs that directly shift myocardial substrate
utilization from NEFA to glucose (e.g., trimetazidine and
ranolazine) and also to drugs like beta blockers that are able
to interfere with the changes in systemic and myocardial
metabolism induced by catecholamines and eventually by the
presence or absence of ischemia [30].
The small number of subjects per group, due to the
complexity of the experimental procedure, is a potential
limitation of this study. However, our main hypothesis that
an impaired glucosemetabolismmight prevent themetabolic
changes described in the myocardium of patients with DCM
can be rejected with a high level of confidence having
observed in AGT patients, if any, a more severe metabolic
derangement. The use of pacing as a tool to stimulate
myocardial metabolism is a limitation since in physiology
the extra cardiac work is normally associated with hormonal
(essentially catecholamines) and substrate changes (NEFA
mobilization); however, our choice was dictated by the need
of constant plasma substrates concentration (required for
the use of metabolic tracers) and by the constraints of the
Catheterization Laboratory setting. The lack of a control
group with normal glucose metabolism and normal heart
function is also a limitation of our study. However, this
choice was related to the fact that these subjects are very
rare among those who undergo a coronary angiography and,
most importantly, ourmajor concern was to avoid attributing
the differences observed in myocardial metabolism between
AGT and NGT patients with DCM to the presence of
AGT, whose impact on myocardial metabolism has not been
carefully characterised.
5. Conclusions
The presence of mild derangements in glucose metabolism
(IGT and early diabetes) exacerbates the metabolic shift from
fat to carbohydrates that occurs at rest in the myocardium
of patients with dilated cardiomyopathy and also the
already poor metabolic flexibility of the tissue in facing an
acute myocardial workload increase. This might render the
myocardium less efficient and/or more vulnerable and might
modify its response to therapies that interfere with glucose
metabolism.
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